Brown, Katelyn

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 2,096

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.

Ludvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 639

Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon‐like peptide‐1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once‐weekly exenatide and liraglutide

Alatorre, C., Fernández Landó, L., Yu, M., Brown, K., Montejano, L., Juneau, P., Mody, R., & Swindle, R. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementMedication Adherence and Compliance

Cited by 111

Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program.

Lingvay, I., Mosenzon, O., Brown, K., Cui, X., O’Neill, C., Fernández Landó, L., & Patel, H. (2023) · Cardiovascular Diabetology

Diabetes Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 55

Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2)

Frias, J. P., De Block, C., Brown, K., Wang, H., Thomas, M. K., Zeytinoglu, M., & Maldonado, J. M. (2024) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 31